Real-World Evidence More Helpful To US FDA In Cases Of High Clinical Trial Efficacy
Pfizer-funded systematic review of approved oncology applications that contained RWE highlights common deficiencies flagged by FDA and says strength of trial data is a key determinant of the extent to which RWE is needed and considered by the agency.
You may also be interested in...
New draft guidance offers recommendations for translating real-world data from claims or EHR sources to meet FDA data requirements.
Demonstrating that electronic health record and medical claims datasets are fit for purpose, and addressing potential limitations in advance, are key themes of new draft guidance.
The latest drug development news and highlights from our US FDA Performance Tracker.